Panelists discuss how clinicians should interpret Clinical Dementia Rating-Sum of Boxes (CDR-SB) score changes by correlating ...

Experts discuss the most promising applications of bispecifics in solid tumors and other emerging therapeutic areas.

Experts discuss how payer and reimbursement considerations affect access to bispecific therapies in different practice settings.

Experts discuss how institutions can address the resource and bandwidth challenges that come with administering complex therapies like bispecifics.

Experts discuss the role of technology, such as electronic health record (EHR) integration, in improving the operationalization of bispecific antibodies.